Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic Solution
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia, Near Vision, Miosis, Eye Diseases
Trial Timeline
Feb 21, 2023 → Feb 9, 2024
NCT ID
NCT05753189About Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic Solution
Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic Solution is a phase 3 stage product being developed by LENZ Therapeutics for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT05753189. Target conditions include Presbyopia, Near Vision, Miosis.
What happened to similar drugs?
1 of 5 similar drugs in Presbyopia were approved
Approved (1) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05753189 | Phase 3 | Completed |
Competing Products
14 competing products in Presbyopia